Despite antiretroviral therapy (ART), human immunodeficiency virus (HIV)-1 persists in a stable latent reservoir 1, 2 , primarily in resting memory CD4 1 T cells 3, 4 . This reservoir presents a major barrier to the cure of HIV-1 infection. To purge the reservoir, pharmacological reactivation of latent HIV-1 has been proposed 5 and tested both in vitro and in vivo [6] [7] [8] . A key remaining question is whether virusspecific immune mechanisms, including cytotoxic T lymphocytes (CTLs), can clear infected cells in ART-treated patients after latency is reversed. Here we show that there is a striking all or none pattern for CTL escape mutations in HIV-1 Gag epitopes. Unless ART is started early, the vast majority (.98%) of latent viruses carry CTL escape mutations that render infected cells insensitive to CTLs directed at common epitopes. To solve this problem, we identified CTLs that could recognize epitopes from latent HIV-1 that were unmutated in every chronically infected patient tested. Upon stimulation, these CTLs eliminated target cells infected with autologous virus derived from the latent reservoir, both in vitro and in patient-derived humanized mice. The predominance of CTL-resistant viruses in the latent reservoir poses a major challenge to viral eradication. Our results demonstrate that chronically infected patients retain a broad-spectrum viral-specific CTL response and that appropriate boosting of this response may be required for the elimination of the latent reservoir.
HIV-1 establishes latent infection in resting CD4 1 T cells 3, 4 . Recent efforts to eradicate HIV-1 infection have focused on reversing latency without global T-cell activation 5 . However, inducing HIV-1 gene expression in latently infected cells is not sufficient to cause the death of these cells if they remain in a resting state 9 . Boosting HIV-1-specific immune responses, including CTL responses, may be required for clearance of the latent reservoir 9 . CTLs have a significant role in suppressing HIV-1 replication in acute infection [10] [11] [12] [13] [14] . Because of this strong selective pressure, HIV-1 quickly acquires mutations to evade CTL recognition 12, 13, [15] [16] [17] [18] . CTL escape has been studied primarily through the analysis of plasma virus 12, 13, 16, [18] [19] [20] , and CTL-based vaccines have been designed based on conserved epitopes 21, 22 . A systematic investigation of CTL escape in the latent reservoir will be of great importance to the ongoing CTL-based virus eradication efforts, because latent HIV-1 probably represents the major source of viral rebound after treatment interruption. Earlier studies have suggested the presence of CTL escape mutations in proviral DNA 15, 17 , but it remains unclear to what extent the latent reservoir in resting CD4 1 T cells is affected by CTL escape, whether mutations detected in proviral DNA are representative of the very small fraction of proviruses that are replication competent, and, most importantly, whether the CTL response can recognize and clear infected cells after latency is reversed.
To investigate CTL escape variants in the latent reservoir, we deep sequenced the proviral HIV-1 DNA in resting CD4 1 T cells from 25 patients (Extended Data Table 1 ). Among them, 10 initiated ART during the acute phase (AP; within 3 months of infection) while the other 15 initiated ART during the chronic phase (CP) of infection. The sequencing was focused on Gag because it is an important target of the CTL response 23 and is highly conserved, which facilitates the detection of escape variants. Our data show that previously documented CTL escape variants completely dominate the viral reservoirs of nearly all CP-treated patients (Extended Data Fig. 1 and Supplementary Table 1 ). This trend is especially obvious for several well characterized CTL epitopes: the human leukocyte antigen (HLA)-A2-restricted epitope SLYNTVATL (SL9), the HLA-A3-restricted epitope RLRPGGKKK (RK9) and the HLA-B57/58restricted epitope TSTLQEQIGW (TW10) ( Fig. 1a and Extended Data Fig. 1 , highlighted in coloured boxes.). In these epitopes, close to 100% of the sequences harboured escape mutations. Comparison of mutation frequencies between HLA allele-relevant and -irrelevant epitopes in CP-treated patients suggests that the CTL escape mutations identified are specific to each patient's HLA type ( Fig. 1b ). By contrast, except for SL9 from patient AP01 and RK9 from patient AP08, few if any CTL escape mutations were archived in AP-treated patients ( Fig. 1c and Extended Data Fig. 1 ). The striking difference between AP-and CP-treated patients ( Fig. 1c) indicates that, unless treatment is initiated within the first several months of infection, the latent reservoir becomes almost completely dominated by variants resistant to dominant CTL responses.
To confirm that variants detected at high frequency in the latent reservoir represent functional CTL escape mutants, cells from seven CPtreated subjects were tested for reactivity to synthetic peptides representing wild-type and mutant versions of the relevant epitopes. As expected, there were only minimal responses to previously documented CTL escape mutants by patient CD8 1 T cells, and no de novo response was detected ( Fig. 1d and Extended Data Fig. 2) . In contrast, all tested subjects retained a strong response to peptides representing the wild-type epitopes, suggesting that the wild-type virus was initially transmitted, with subsequent evolution of CTL escape variants. Most HIV-1 proviruses detected in patients are defective 24 . Therefore, to determine whether these CTL escape variants can be reactivated and lead to viral rebound if therapy is stopped, we isolated replication-competent viruses from the latent reservoirs of nine CP-treated patients. We found that all the dominant CTL escape mutations that had been identified in proviruses in resting CD4 1 T cells were also present in the replication-competent viruses that grew out after T-cell activation ( Fig. 1e and Extended Data Fig. 3 ), indicating that these CTL escape variants not only dominate the population of proviruses, but can also be released and replicate once latency is reversed.
We next asked whether the host CTL response could recognize and eliminate the cells infected with these escape variants. We infected activated CD4 1 T cells from these patients with autologous, replicationcompetent virus derived from the latent reservoir (Extended Data Fig. 4a ). The infected cells were then co-cultured with autologous CD8 1 T cells, either unstimulated or pre-stimulated, to assess HIV-1-specific cytolytic activity. Non-specific activation of CD8 1 T cells was not observed after co-culture with phytohaemagglutinin (PHA)-activated CD4 1 T cells (Extended Data Fig. 4b ). From all 13 CP-treated subjects tested, CD8 1 T cells pre-stimulated by a Gag peptide mixture efficiently killed autologous infected CD4 1 T cells (median 61% elimination), while unstimulated CD8 1 T cells from most subjects had significantly less effect (median 23% elimination) ( Fig. 2a and Extended Data Fig. 4c, d ). CD8 1 T cells from 7/7 healthy donors completely failed to eliminate autologous infected cells ( Fig. 2a) , confirming that the observed killing was HIV-1 specific. The killing effect was enhanced by increasing the effector to target ratio (Extended Data Fig. 5a ), and was cell-cell contact dependent (Extended Data Fig. 5b ). When the co-culture was maintained over time in the absence of ART, viral replication was significantly reduced, but not completely inhibited by pre-stimulated CD8 1 T cells ( Fig. 2b ). We found that peptide mixtures from other HIV-1 proteins (Nef, Tat, Rev and Env) could also boost CTL responses and facilitate the elimination of infected cells (Fig. 2c) , and that CTLs pre-stimulated by Gag peptides generally had the highest activity. Together, these results demonstrate that chronically infected patients retain CTL clones that can recognize and eliminate autologous infected CD4 1 T cells, despite the presence of CTL escape mutations in dominant epitopes. However, these clones require stimulation with antigen for optimal activity.
To characterize further which CTL population contributed to the elimination of cells infected by CTL escape variants, we compared the killing activity of two specific CTL populations: the population that targets epitopes in which escape has been identified and the one that targets unmutated epitopes ( Fig. 3a ). CD8 1 T cells from patients CP36 and CP39 were pre-stimulated with interleukin (IL)-2 and different synthetic peptides representing the wild-type forms of the relevant epitopes. After incubation for 6 days, each CTL population exhibited significant proliferation compared with no treatment or IL-2 alone (Fig. 3b , c). Pentamer staining for three available epitopes revealed that the number of epitopespecific CD8 1 T cells increased dramatically after stimulation with wildtype peptides (Fig. 3b ). After co-culture with autologous target cells infected with latent reservoir-derived viruses, CTLs targeting unmutated epitopes clearly showed stronger cytolytic activity than the IL-2 only controls, while CTLs targeting epitopes with identified escaped mutations showed no significant killing ( Fig. 3d ). CTLs pre-stimulated by the Gag peptide mixture exhibited stronger killing than all singlepeptide-stimulated populations (Fig. 3d ).
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To test whether CTLs that recognize unmutated viral epitopes can inhibit HIV-1 replication and clear infected cells in vivo, we generated patient-derived humanized mice using an improved version of a recently reported mouse system named MISTRG 25 . Whereas the previously reported MISTRG mice bear a bacterial artificial chromosome (BAC) transgene encoding human SIRP-a, the newly generated MIS (KI) TRG mice harbour a knock-in replacement of the endogenous mouse Sirpa gene with a humanized version. With humanization by knock-in replacement of the Csf1, Csf2, Il3, Tpo and Sirpa genes in the Rag2 2/2 Il2rg 2/2 genetic background, MIS (KI) TRG mice are highly permissive for human haematopoiesis and support the reconstitution of robust human lymphoid and myelomonocytic systems. With the demonstrated development of functional T lymphocytes and monocytes/macrophages, MIS (KI) TRG mice provide a useful humanized mouse host for HIV-1 infection studies. Bone marrow biopsies were obtained from study participants and 
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purified CD34 1 cells were used to reconstitute the MIS (KI) TRG mice. We infected these patient-derived humanized mice with primary HIV-1 isolates grown from resting CD4 1 T cells from the same patient and then evaluated the antiviral effect of autologous CD8 1 T cells ( Fig. 4a ). MIS (KI) TRG mice engrafted with bone marrow CD34 1 cells from patient CP18 successfully developed human T-lymphocyte and monocyte/ macrophage subsets (Fig. 4b, c ), which were sufficient to support HIV-1 infection (Fig. 4d ). Plasma HIV-1 RNA levels peaked 20-30 days after infection (Extended Data Fig. 6a ). Depletion of CD4 1 T cells was clearly evident 12 days after infection in peripheral blood and spleen ( Fig. 4e and Extended Data Fig. 6b, c) . Cell-associated HIV-1 RNA was detected in both T cells and macrophages/monocytes (Extended Data Fig. 6d ). Viral infection was also observed in various tissues in which a large number of memory CD4 1 T cells were detected (Extended Data Fig. 7 ). In control mice or mice that received autologous patient CD8 1 T cells pre-stimulated with a peptide representing the unmutated dominant SL9 epitope, levels of plasma HIV-1 RNA and proviral DNA in peripheral blood continued to increase from day 14 to day 29 after infection (Fig. 4f ). In sharp contrast, mice that received CD8 1 T cells pre-stimulated with unmutated epitopes (Gag mix or WF9) had a significantly lower level of viral replication ( Fig. 4g , h). Dramatic decreases in plasma HIV-1 RNA of 100-to 1,000-fold were observed in all three mice that received CD8 1 T cells pre-stimulated with the mixture of Gag peptides including dominant and subdominant epitopes. Two of three mice had undetectable levels of plasma HIV-1 RNA and proviral DNA in peripheral blood measured at three time points ( Fig. 4g ). We performed the same experiments using patient CP36-derived humanized mice and a reduction of peripheral HIV-1 RNA and DNA levels was also observed in mice that received CP36 CD8 1 T cells pre-stimulated with the mixture of Gag peptides (Extended Data Fig. 8 ). Since the postengraftment lifespan of MIS (KI) TRG mice is only 10-12 weeks 25 , we were only able to investigate the acute phase of HIV-1 infection and demonstrate the in vivo functionality of patient CD8 1 T cells. Future developments of the MIS (KI) TRG model will prolong the post-engraftment lifespan of these mice and allow studies of the establishment and clearance of the HIV-1 latent reservoir in vivo. Together, our in vitro and in vivo experiments demonstrate that only CTL clones targeting unmutated epitopes are effective against cells infected with the viral variants that are likely to represent the major source of rebound HIV-1 after reversal of latency. The seeding of the HIV-1 latent reservoir starts just a few days after infection 26 , before the development of a robust CTL response 14 . This is consistent with our finding that patients who initiated treatment early, in the acute infection stage, have few if any CTL escape variants archived in the latent reservoir. However, if treatment was initiated in chronic infection, CTL escape variants became dominant in the latent reservoir, indicating a complete replacement of the initially established 'wild-type' reservoir. The mechanism behind this replacement warrants further investigation, but probably reflects the dynamic nature of the reservoir in untreated infection. In any event, the overwhelming presence of escape variants in the latent reservoir of chronic patients certainly presents an additional barrier to eradication efforts. The striking difference between AP-and CP-treated patients presents another argument for early treatment of HIV-1 infection; early treatment not only reduces the size of the latent reservoir 27 , but also alters the composition of the reservoir, as shown here, in a way that may enhance the efficacy of potential CTL-based eradication therapies.
The hierarchy of HIV-1-specific CTL response in acute infection appears to have an important role in initial viral suppression, as demonstrated by the fact that certain immunodominant CTL populations are frequently linked to lower set point viraemia later in infection 17, 28 . These immunodominant responses in acute infection have been identified as the major selection force driving the development of CTL escape mutations 13, 20 . Here we show that these immunodominant responsedriven mutations are not only archived in the latent reservoir, but also in fact dominate the latent provirus population in CP-treated patients.
Therefore, directing CTL responses to unmutated viral epitopes is essential to clear latent HIV-1. Owing to bias in antigen presentation or recognition 29 , common vaccination strategies will probably re-stimulate immunodominant CTL clones that do not kill infected cells after the reversal of latency. Stimulation of CTL responses with viral peptides circumvents antigen processing and is able to elicit broad-spectrum CTL responses against unmutated regions of viral proteins. Our study suggests that latent HIV-1 can be eliminated in chronically infected patients despite the overwhelming presence of CTL escape variants. 
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METHODS
Human subjects. Peripheral blood or bone marrow for the isolation of primary CD4 1 , CD8 1 T cells or CD34 1 cells was obtained from 30 HIV-1-infected patients (Extended Data Table 1 ) and 7 healthy adult volunteers. All patients had been on ART for at least 2 years and had maintained undetectable plasma HIV-1 RNA levels (,50 copies per ml) for at least 1 year before study. Ten AP-treated patients were recruited from the OPTIONS cohort at the University of California San Francisco (UCSF). This study was approved by the Johns Hopkins Internal Review Board and by the UCSF Committee on Human Research. Written informed consent was provided by all study participants. HLA typing for each patient was performed by the Johns Hopkins University Immunogenetics Laboratory. Sample preparation for deep sequencing. Peripheral blood mononuculear cells (PBMCs) were isolated from whole blood by Ficoll gradient separation. CD4 1 T cells were purified from PBMCs by negative selection using CD4 1 Isolation Kit II (Miltenyi). Resting CD4 1 T cells were then purified from CD4 1 T cells by negative selection using CD25, CD69 and HLA-DR microbeads (Miltenyi). Genomic DNA was extracted from 5 million resting CD4 1 T cells from each patient using QIAamp DNA Mini Kit (Qiagen). The gag gene was amplified from genomic DNA by a tworound nested PCR using these primers: 59 outer primer (59-TTGACTAGCGGAG GCTAGAAGG-39); 39 outer primer (59-GATAAAACCTCCAATTCCCCCTAT C-39); 59 inner primer (59-GAGAGATGGGTGCGAGAGCGTC-39); 39 inner primer (59-CTGCTCCTGTATCTAATAGAGC-39). For each patient, the entire genomic DNA from 5 million resting CD4 1 T cells was evenly distributed as a template into 80 PCR reactions. The reactions were performed by using High Fidelity Plantinum Taq Polymerase (Life Technologies) following the manufacturer's instructions. PCR amplicons were purified by gel extraction after gel electrophoresis.
Deep sequencing. For PacBio RS single-molecule sequencing, amplicons were barcoded with a group of 10 bp indexes and then multiple samples were pooled together to generate a SMRTbell sequencing library following the Pacific Biosciences template preparation and sequencing-C2 user guide for 2 kb insert size and using the Pacific Biosciences DNA template preparation kit. For MiSeq sequencing, the pooled amplicon DNA was end repaired, adenylated, and ligated to Illumina TruSeq adaptors and PCR enriched for 10 cycles. The resulting library was then run on a bioanalyser high-sensitivity DNA chip for size and concentration determination. The library was then sequenced on MiSeq for paired-end 250 bp reads. The sequence reads from PacBio and MiSeq were demultiplexed using Fastx-Toolkit. Data analysis for deep-sequencing results. For the paired MiSeq reads, the two reads were first merged using FLASH 31 . MiSeq and PacBio reads from each individual were then aligned to the reference HIV-1 consensus B Gag sequence using Bowtie2 (ref. 32) . A custom program was written using Perl scripts to identify and compute the frequency of all sequence variants that caused non-synonymous amino acid changes in each individual's relevant optimal Gag epitopes (based on reported information in the HIV Molecular Immunology Database, Los Alamos National Laboratory (http://www.hiv.lanl.gov/content/immunology/index.html)) according to their HLA type. For each individual, variants that occurred at a frequency .3% were retained. Additionally, for PacBio reads, sequences with identified premature stop codons were eliminated from the analysed results. For each identified variation, the mutation type regarding CTL recognition was determined by matching with the information in the before-mentioned database. The five mutation types adopted in this paper are: documented escape (no CTL response when patient cells are challenged with the variant peptide); inferred escape (variant is predicted to be an escape mutant by longitudinal study or transmission study, but the reactivity of the variant is not tested experimentally); diminished response (experimental data suggest partial escape as evidenced by decreased CTL response); susceptible form (CTL response is elicited when patient cells are challenged with the variant peptide); and mutation type not determined (no experimental data on CTL recognition of this variant). ELISpot assays. The ELISpot assays were performed using Human IFN-c ELISpot PLUS kit (Mabtech) according to methods previously described 33 and the manufacturer's instructions. PBMCs were added at 200,000 cells per well and synthetic peptides were added in a final concentration of 0.1, 1 or 10 mg ml 21 . A response was considered positive if it was threefold higher than the mean background (cell only control) and greater than 55 SFC per million cells. The number of specific T cells was calculated by subtracting the mean background values. Recovery and sequencing of patient viruses from resting CD4 1 T cells. Coculture assays were performed to recover and amplify replication-competent viruses as previously described 34 . The viruses were recovered from 5-10 million resting CD4 1 T cells. The concentration of outgrowth viruses was determined by p24 ELISA (PerkinElmer). Total RNA of outgrowth viruses was extracted using TRIzol LS reagent (Life Technologies). Residual DNA was then removed by TURBO DNase (Life Technologies) treatment. First-strand complementary DNA was synthesized using SuperScript III Reverse Transcriptase (Life Technologies) and the gag gene was amplified from cDNA using the gag outer primer pair mentioned above. The PCR amplicons were then purified by gel extraction and sequenced by regular Sanger sequencing.
In vitro HIV-1 infection. PBMCs from HIV-1-infected patients and healthy donors were stimulated by adding 0.5 mg ml 21 PHA and IL-2 (100 U ml 21 ) to basal media (RPMI with 10% heat-inactivated fetal bovine serum and antibiotics) for 3 days before isolation of CD4 1 T cells. Each patient's activated CD4 1 T cells were infected with viruses recovered from the same patient's resting CD4 1 T cells. Healthy donors' CD4 1 T cells were infected with a laboratory strain virus, BaL. The virus concentration used in infection was equivalent to the p24 concentration of 200 ng ml 21 . All infections were performed by centrifugation of target cells with virus at 1,200g for 2 h. Stimulation of CD8 1 T cells. PBMCs from CP-treated patients were cultured in the presence of IL-2 (100 U ml 21 ) with a mixture of consensus B Gag (or Nef, Rev, Tat, Env) peptides (800 ng ml 21 for each) (NIH AIDS Reagent Program), or with individual synthetic peptide (0.5 mg ml 21 ) (Genemed Synthesis). CD8 1 T cells were purified after 6 days of incubation by positive selection using human CD8 microbeads (Miltenyi). To monitor CTL proliferation, PBMCs were stained with CFSE (Life Technologies) before incubation and with the relevant pentamer (Proimmune) after incubation. PBMCs were then stained with CD8-APC (Becton Dickson (BD)) and analysed by flow cytometry using FACS Canto II (BD).
Co-culture of autologous CD4 1 and CD8 1 T cells. Three hours after infection, CD4 1 T cells were mixed with autologous unstimulated or stimulated CD8 1 T cells at a 1:1 ratio in basal media at 5 million cells per ml. Two days after co-culture, enfuvirtide (T-20, Roche) was added into the culture at 10 mM to prevent further infection events except if the measurement was p24 ELISA. Three days after coculture, cells were stained with CD8-APC (BD) first, fixed and permeabilized with Cytoperm/Cytofix (BD pharmingen), then stained for intracellular p24 Gag (PE, Coulter). Cells were analysed by flow cytometry using FACS Canto II (BD). For measurement of viral growth, 5 ml of supernatant was taken from the co-culture at days 0, 3 and 6, and subjected to p24 ELISA. For analysis of cell contact dependence, CD4 1 and CD8 1 T cells were placed in separate chambers of trans-well plates (0.4 mm, Costar). Generation and infection of patient-derived humanized mice. The previously reported MISTRG mouse in the Rag2 2/2 Il2rg 2/2 129 3 Balb/c (N2) genetic background harbours knock-in replacements of the endogenous mouse Csf1, Csf2, Il3 and Tpo genes with humanized versions and a BAC transgene encoding human SIRP-a 25 . We generated the Sirpa (KI) mouse, which harbours a knock-in replacement of the endogenous mouse Sirpa gene with a humanized version. The Sirpa (KI) mouse will be thoroughly described elsewhere (manuscript in preparation). The improved MIS (KI) TRG mouse was generated by breeding Sirpa (KI) mice to MITRG mice. All animal experimentations were performed in compliance with Yale Institutional Animal Care and Use Committee protocols. MIS (KI) TRG mice were maintained with continuous treatment with enrofloxacin in the drinking water (Baytril, 0.27 mg ml 21 ). Patient bone marrow or fetal liver CD34 1 cells were isolated by CD34 microbeads selection (miltenyi). Newborn mice (within their first 3 days of life) were sublethally irradiated (X-ray irradiation with X-RAD 320 irradiator, PXi; 1 3 150 cGy) and 100,000 fetal liver or 250,000 patient CD34 1 cells in 20 ml of PBS were injected into the liver with a 22-gauge needle (Hamilton Company). Both male and female mice with comparable engraftment levels (percentage of hCD45 1 , hCD3 1 and hCD14 1 cells in the blood) were separated randomly into the experimental groups 6-8 weeks after engraftment. Mice engrafted with patient CD34 1 cells were infected by retro-orbital injection with HIV-1 (100 ng p24), which was recovered and expanded from the resting CD4 1 T cells of the same patient (CD34 1 cell donor), as mentioned earlier. Mice engrafted with fetal liver CD34 1 cells were infected by intravenous injection with HIV-1 BaL (100 ng p24). Mice with less than 5% human CD45 1 cells in the peripheral blood were excluded from the infection study. Mice with more than 70% human CD45 1 cells in the peripheral blood were also excluded because they were unhealthy due to human macrophage/monocytecaused anaemia 25 . Twenty million autologous CD8 1 T cells with or without prestimulation were injected intravenously 9 or 14 days after infection. Group allocation was blinded. Peripheral blood samples were collected by retro-orbital bleeding at different time points before and after injection of CD8 1 T cells. Engraftment of human CD45 1 cells as well as lymphoid and myeloid subsets was determined by flow cytometry. Plasma HIV-1 RNA in peripheral blood was measured by one-step reverse transcriptase (Invitrogen) real-time PCR using the following primers and probe, described previously 8 : forward (59 R 39) ACATCAAGCAGCCATGCAAAT, reverse (59 R 39) TCTGGCCTGGTGCAATAGG, and probe (59 R 39) VIC-CTA TCCCATTCTGCAGCTTCCTCATTGATG-TAMRA. Assay sensitivity is 200 RNA copies per ml of plasma. HIV-1 DNA in peripheral blood was also measured by realtime PCR using the same primers and probe mentioned earlier, with assay sensitivity at 5 copies per 100 ml of blood. Total viral DNA in PBMCs was determined by measuring copies of viral DNA per 100 ml blood and blood volume per mouse (80 ml blood per 1 g body weight). To quantitate total viral DNA in tissues, spleens, The generation of patient CP36-derived humanized mice is described in Fig. 4 . Mice were infected with autologous viruses at 6 weeks old. CD8 1 T cells from patient CP36 were pre-stimulated with the mixture of Gag peptides or left untreated for 6 days in vitro, and were injected into mice intravenously 9 days after infection. Plasma HIV-1 RNA (a) and HIV-1 DNA (b) in peripheral blood were measured by real-time PCR.
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